• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
180343 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

" @9 D, B* S& H# n7 i2 ^  ^- Q- T/ \3 @可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  4 q, {  j+ g" Z* ^( b* R- D6 ]
7 A. v" |% B6 L1 c2 a0 K) ?
% u/ r! l6 ?8 i' a; p, o
Sub-category:2 v- k$ }0 [5 T0 @: D
Molecular Targets + ~; q8 C! t" I% ?. D# Y

" C) @  g" x3 \9 ~. q- Y6 t* R/ V4 K6 `2 m
Category:: X% a* R* @; k" O; s8 A
Tumor Biology 1 n' h+ e& v) h# v% [- W7 ]

8 p8 P4 W9 a3 c& K
0 x; i8 C* G/ l  j& X  S( @Meeting:
, X& `- R) s. u& ?2 l% A: {4 `2011 ASCO Annual Meeting
8 [: `, P- n9 Y/ {$ G
3 J$ ]2 w. |" ?3 u0 G
& M" o5 ?# X8 T7 R$ y" e: tSession Type and Session Title:. [* [3 y0 n4 b4 U0 L% a8 |7 D
Poster Discussion Session, Tumor Biology 1 Z: |( C. S# D6 o  M+ b

( b) p0 m+ R% n# `) |. o; d1 [' l/ a& x8 j0 V8 X8 \
Abstract No:
! i/ }" x- E* y- `, i  ~: @10517 1 H; N% |8 A+ u; `
/ ]. y2 a4 s3 D* s
- F% f1 d; u8 r/ O/ T2 V- D" N
Citation:
' x5 K3 H  ]% b8 Q' `J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 e8 A9 ~/ y; d. N
) B. E5 \- ^& F' p
# ^! U% ~' T8 W- U8 i
Author(s):
1 B5 C7 J5 b5 JJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 6 z5 A2 K$ R: }9 s# F& m; B$ a

. ?2 u3 S, _0 C1 G8 N# Q- y) A3 i6 u8 G6 T8 [5 L% y) _  Y
) l( B5 Y# w9 ~$ k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.* G& q9 y- w- p( l6 B

2 t9 k1 {% _2 d: l9 @7 zAbstract Disclosures! s- f' h& ^# F# d0 ~! ^
. ?" M' Q' @7 |9 m" s( P* Y
Abstract:+ ^. U; _4 {. Z9 [( T' |# m' J
. R  n! X9 A- c7 B& x

- n: d8 X, F% y1 B( w1 `# vBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ o8 S; h5 W; v2 |0 [
/ f8 W$ h; ^8 M5 G  h  W
  j" g6 Y; }( J. R
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 % j2 n! k3 Y' y+ J
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
$ u* W- {1 b0 e0 a+ y; c
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 / W" z! t, z. C/ \
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
; s0 Q+ L; Q0 m3 Z" |* W! D2 U- u) u' xALK一个指标医院要900多 ...
2 {& C( `1 ]. [8 k" ]6 q
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
( g/ F1 ^0 E) |4 U" q: q2 W% z- `8 V7 J+ V" e  L% r
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表